The non-profit La Jolla Institute for Allergy and Immunology said last week that it has licensed to MedImmune the intellectual property rights to a discovery that could serve as the basis for a new biologic treatment for asthma.

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the La Jolla Institute, which established a dedicated tech-transfer department in 2007 as part of an institute-wide effort to diversify its revenue sources before funding from sole corporate sponsor, Kirin Pharma USA, dries up in 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.